TIGIT and neoplasm: For OAS, patients with a lower intratumoral TIGIT expression in CD3+ cells showed a 5-year survival of 38.3%, whereas tumor patients with overexpression of TIGIT in CD3+ cells displayed a 5-year OAS of 55.2% (p = 0.025, Figure 4a).